TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03482076

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transferrin receptor concentration
Description: Sandwich radio-imunoassay
Study: NCT01311518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo
Description: Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Injectable Thymosin beta 4
Description: Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
Study: NCT00331513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02669082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets
Study: NCT03932149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
Study: NCT02034812

Intervention type: OTHER
Intervention: Decipher Questionnaire
Description: Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
Study: NCT02930746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
Study: NCT00971035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study: NCT06021756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: Ketamine
Description: Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
Study: NCT02494375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep and glucose assessments
Description: Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
Study: NCT01366859

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice Protein (Placebo)
Description: The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
Study: NCT04649918

Intervention type: OTHER
Intervention: pulmonary rehabilitation
Description: COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program

Intervention type: OTHER
Intervention: pulmonary rehabilitation
Description: COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
Study: NCT03326284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 g protein hypocaloric
Description: Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35 g protein hypocaloric
Description: Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 g protein hypocaloric
Description: Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35 g protein energy balance
Description: Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
Study: NCT03936335

Intervention type: DRUG
Intervention: dupilumab
Description: No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
Study: NCT04678427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Functional Test
Description: Complete 6-minute walk test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in walking and other activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Get Up and Go Test
Description: Complete timed get up and go test
Study: NCT01794793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
Study: NCT03962543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Description: Mirdametinib (PD-0325901) capsule or dispersible tablet
Study: NCT04291664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate 1000mg will be administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5Mg Tab
Description: Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DST-2970 (Abiraterone)
Description: DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
Study: NCT04308980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Specialized product for medical nutrition (SPP-1)
Description: Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized diet
Description: All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: individualized diet
Description: All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
Study: NCT02036658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
Study: NCT01027728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX 354-C
Description: * Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days.
Study: NCT02400567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracile

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study: NCT03701698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet
Description: Ruxolitinib Oral Tablet （Jakafi）, 5\~10mg bid po for at least 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
Study: NCT02873637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: under sartorial catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: femoral catheter
Study: NCT04836364

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention; observation only.
Study: NCT00415597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Description: capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
Study: NCT03646305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Defusion
Description: Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Defusion
Description: Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
Study: NCT03147859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab (brand name Entyvio)
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab (brand name Entyvio)
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab (brand name Entyvio)
Description: IV infusion
Study: NCT04329091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
Study: NCT02193139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 12 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 18 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WL8713, 24 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04198584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VC-CBCS
Description: A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
Study: NCT00722566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE Administered by subcutaneous injection
Description: Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VELCADE Administered by intravenous infusion
Description: Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
Study: NCT03870776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP4343
Description: Daily oral administration of MAP4343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP4343
Description: Daily oral administration of MAP4343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration of Placebo
Study: NCT04045184

Intervention type: OTHER
Intervention: Food assistance
Description: This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
Study: NCT01276522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Monthly subcutaneous injection with 150mg Canakinumab for 6 months
Study: NCT00381238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Extended Release Tablets
Study: NCT00067769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based intervention UCanPoopToo
Description: Internet-based intervention to administer Enhanced Toilet Training (ETT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: Routine clinical care.
Study: NCT03508752

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery dose is based on the largest tumor size
Study: NCT03750747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter
Description: SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing \<10 kg, the sensor will be placed on the big toe. For patients weighing \>10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
Study: NCT01370824

Intervention type: PROCEDURE
Intervention: Punch biopsy
Description: Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.

Intervention type: PROCEDURE
Intervention: Surgical excision
Description: Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds.
Study: NCT01103102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocide Oral Rinse
Description: Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocide Oral Rinse
Description: Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocide Oral Rinse
Description: Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02326922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metraplant-E levonorgestrel-releasing intrauterine device
Description: Metraplant-E insertion and follow up for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metraplant-E levonorgestrel-releasing intrauterine device
Description: Metraplant-E insertion and follow up for 6 months
Study: NCT01060605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
Study: NCT03912818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cystectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT04358068

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Hydroxychloroquine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Azithromycin
Description: Administered orally
Study: NCT01936298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-ROM Continuous Passive Rehabilitation
Description: Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-ROM Continuous Passive Rehabilitation
Description: Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually).
Study: NCT00819013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Vaccine: ACAM FLU-A
Description: 0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Vaccine: ACAM FLU-A
Description: 0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Vaccine: ACAM FLU-A
Description: 0.5 mL ACAM FLU-A low dose, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 0.5 mL, Intramuscular